Oncobiologics to Present at the World Biosimilar Congress 2017
09 Mai 2017 - 3:00PM
Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage
biopharmaceutical company focused on identifying, developing,
manufacturing and commercializing complex biosimilar therapeutics,
today announced that Pankaj Mohan, Ph.D., Chairman and Chief
Executive Officer of Oncobiologics, will participate and present at
the World Biosimilar Congress 2017 taking place May 23 – 24, 2017.
Event: The World Biosimilar
Congress 2017 Presentation Date: May 23-24,
2017 Location: Hilton San Diego Resort and
Spa, San Diego, CA
Dr. Mohan will present on “Production efficiency:
Streamlining both the development and manufacturing process,” on
May 23rd at 3:20 p.m. On the same day, Dr. Mohan will also
participate in a panel discussion on Intellectual Property at 5:00
p.m. On May 24th at noon, he will moderate a roundtable discussion
of industry executives on “Achieving required data for regulatory
and commercial approvals.”
World Biosimilar Congress
2017
To learn more about the World Biosimilar Congress
and to register for the conference please visit
http://www.terrapinn.com/conference/biosimilar-congress-usa/index.stm
About Oncobiologics, Inc. and its
BioSymphony™ Platform
Oncobiologics is a clinical-stage biopharmaceutical
company focused on identifying, developing, manufacturing and
commercializing complex biosimilar therapeutics. Its current focus
is on technically challenging and commercially attractive
monoclonal antibodies (mAbs) in the disease areas of immunology and
oncology. Oncobiologics is advancing its pipeline of eight
biosimilar products, two of which are currently in clinical
development. Led by a team of biopharmaceutical experts,
Oncobiologics operates from an in-house state-of-the-art fully
integrated research and development, and manufacturing facility in
Cranbury, New Jersey. Oncobiologics employs its BioSymphony™
Platform to address the challenges of biosimilar development and
commercialization by developing high quality mAb biosimilars in an
efficient and cost-effective manner on an accelerated timeline. For
more information, please visit www.oncobiologics.com
CONTACTS:
Oncobiologics:
Lawrence A. Kenyon
Chief Financial Officer
LawrenceKenyon@oncobiologics.com
Media & Investors:
Alex Fudukidis
Russo Partners, LLC
alex.fudukidis@russopartnersllc.com
ONCOBIOLOGICS, INC. (NASDAQ:ONS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
ONCOBIOLOGICS, INC. (NASDAQ:ONS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024